Retatrutide week-one weight drop claims: what's real?

What did @cammcdfitness actually say?

The creator's core claim is straightforward: if the scale drops fast in week one of retatrutide, "it's not going to be all fat." They attribute early weight loss to water, glycogen depletion, reduced food volume in the gut, and less bloating from decreased appetite. They also reassure viewers that rapid early loss does not mean muscle is being lost, calling it "mostly just waterway and glycogen." That's the argument in full, and it's worth taking seriously because it's one of the more grounded pieces of advice you'll see in the peptide corner of TikTok. The creator isn't promising dramatic fat loss. They're managing expectations, which is genuinely unusual in this space. They even frame real fat loss as "the boring part" that requires calorie consistency, daily steps, and adequate protein over weeks, not days. That framing deserves credit before we pick at the edges.

Does the science back this up?

Yes, mostly. The early rapid weight loss seen with GLP-1 class and multi-agonist peptides is well-documented and is not primarily fat mass. Glycogen stored in muscle and liver binds water at roughly a 3:1 ratio by weight, so when food intake drops sharply, glycogen depletes and water follows. Studies on low-calorie interventions consistently show this effect in the first one to two weeks.

Retatrutide is a GIP, GLP-1, and glucagon triple agonist currently in phase 3 trials. The phase 2 data published by Jastreboff et al. (2023, New England Journal of Medicine) showed significant total body weight reduction over 24 weeks, but week-by-week body composition data was not broken out publicly. However, research on similar agents like tirzepatide (Gastaldelli et al., 2022, Nature Medicine) confirmed that early weight loss is disproportionately water and lean mass effects stabilize as fat loss continues. The creator's timeline and mechanism are consistent with this literature.

What did they get wrong (or right)?

They got the mechanism right. Glycogen and water depletion driving early scale movement is textbook physiology and matches what we see in GLP-1 receptor agonist literature. The reassurance about muscle loss is also reasonable. Early rapid scale drops with appetite-suppressing agents are not primarily lean mass losses, particularly if protein intake is maintained, which the creator specifically recommends.

Where they are slightly incomplete: the claim that you "don't lose muscle" is too breezy. Prolonged aggressive caloric restriction on any agent, including retatrutide, can contribute to lean mass loss over time. Churchward-Venne et al. (2020, Journal of Physiology) and the SURMOUNT trial analyses both flag this risk during extended caloric deficits. The creator does mention protein, which is the right mitigation, but glossing over the longer-term lean mass risk is a gap worth noting. They also use the word "Rheta" throughout, likely referring to retatrutide, but never name the compound formally or acknowledge it is not approved for clinical use in any jurisdiction as of 2024.

What should you actually know?

Retatrutide is not an approved medication. It is an investigational compound that has shown strong results in phase 2 trials but has not completed phase 3 and has not been approved by the FDA, MHRA, or any major regulatory body as of mid-2024. Anyone using it is doing so outside of a clinical trial, which means dose, purity, and sourcing are unverified risks the video does not address at all.

That said, the physiological explanation the creator gives for week one weight loss is accurate and worth understanding. If you start any appetite-suppressing agent and lose four to six pounds in seven days, you have not lost four to six pounds of fat. That would require a caloric deficit of roughly 14,000 to 21,000 calories in a week, which is physiologically implausible for most people. The scale moved because glycogen stores dropped and water followed. Real fat loss is slower, less dramatic on the scale, and shows up over weeks and months with consistent behavior. The creator is right about that, and more influencers in this space should say it.

Bottom line

This video is one of the more scientifically honest pieces of retatrutide content circulating on TikTok. The core physiology is accurate. The expectations-setting is genuinely useful. The gaps are the incomplete picture on long-term lean mass risk and the complete absence of any regulatory or safety context around an unapproved investigational compound. Take the weight loss explanation at face value. Do not take the implicit safety framing the same way.